Comorbidity in myasthenia gravis

INTRODUCTION . Myasthenia gravis is an autoimmune disorder characterized by pathological muscle weakness and fatigability. Patients with myasthenia often present with various comorbidities, including cardiovascular and thyroid diseases, systemic autoimmune disorders, as well as mental health conditions such as depression and anxiety disorders. The impact of these comorbidities on the severity of myasthenia remains ambiguous. AIM. To evaluate the structure and influence of comorbid conditions on the course of myasthenia gravis in patients with varying disease severity. MATERIALS AND METHODS . A clinical analysis was conducted on 102 patients with myasthenia gravis who underwent treatment between 2020 and 2023 at the Almazov National Medical Research Centre and the City Multidisciplinary Hospital No. 2 at St. Petersburg. Demographic characteristics, comorbidities, and myasthenia severity (MGFA classification) were assessed. A comparative analysis was performed for groups with different disease severities. RESULTS . The most common comorbid conditions were anxiety disorders, depression (40.2 %) and hypertension (37.3 %). Mental health disorders were more prevalent in patients younger than 40 years, whereas cardiovascular diseases dominated in patients over 60 years. No significant association was found between these comorbidities and the severity of myasthenia. CONCLUSION . Despite the high prevalence of comorbid conditions, their impact on the severity of myasthenia gravis has not been identified. Further research is required to elucidate the mechanisms of interaction between myasthenia gravis and comorbidities.